Sysmex Inostics Unveils Approved RAS-RAF-SEQ Assay
Sysmex Inostics Inc., a biotechnology company focused on research and a subsidiary of Japan's Sysmex Corporation, is excited to share that its groundbreaking RAS-RAF-SEQ Laboratory Developed Test has received approval from the New York State Department of Health Clinical Laboratory Evaluation Program for clinical trial use. This approval signifies a major step forward in the diagnosis and treatment of cancer.
Overview of the RAS-RAF-SEQ Assay
The RAS-RAF-SEQ assay is a cutting-edge advancement in liquid biopsy technology. As a clinically validated diagnostic tool, it identifies five vital genetic targets associated with several cancers influenced by the RAS-RAF and PI3K pathways. These include colorectal, pancreatic, gallbladder, ovarian, and lung cancers. This test promises to provide valuable insights for tailored therapies specific to each patient.
Importance of NY State CLEP Approval
Shinichi Sato, the President and CEO of Sysmex Inostics, highlighted the significance of the NY State CLEP approval. He remarked, "This will offer pharmaceutical and clinical trial researchers in New York a non-invasive way to gain deeper insights into innovative treatment strategies for a variety of RAS-RAF and PI3K-related cancers." This non-invasive strategy represents a groundbreaking shift in patient care, showcasing Sysmex Inostics' dedication to delivering advanced diagnostic solutions.
Understanding the RAS-RAF Pathway
Mutations within the RAS-RAF signaling pathway, particularly those involving KRAS, NRAS, and BRAF, are commonly seen in various types of cancer. These genetic changes are crucial for understanding how cancer progresses and can significantly affect treatment responses. By detecting these mutations through the RAS-RAF-SEQ assay, healthcare professionals can choose the most appropriate treatments, ultimately improving patient care.
Ultra-sensitive Detection with Plasma-Safe-SeqS
A notable feature of the RAS-RAF-SEQ assay is its Plasma-Safe-SeqS technology, which effectively preserves all input molecules during testing. This innovative approach allows for the detection of low-frequency genomic mutations with exceptional sensitivity. Jonathan Craft, Associate Director of Translational Research at Sysmex Inostics, expressed the significance of this advancement, stating, "The RAS-RAF-SEQ assay offers ultra-sensitivity with strong specificity for targeted mutations in the RAS-RAF and PI3K pathways, ensuring accurate diagnostics."
Enhancing Cancer Treatment Outcomes
The RAS-RAF-SEQ assay not only pinpoints existing mutations but also monitors new resistance mutations that may develop during treatment. By offering a comprehensive view of a patient's genetic makeup, this test aids in making well-informed therapeutic decisions, ensuring high-quality care while minimizing adverse treatment effects.
About Sysmex Inostics
Sysmex Inostics is celebrated for its groundbreaking work in personalized medicine and serves as a leading biotechnology firm and CLIA-certified laboratory. Since launching its OncoBEAM™ platform in 2008, Sysmex Inostics has continually strived to improve the detection of low-frequency biomarkers through next-generation sequencing panels, achieving remarkable allele frequency sensitivity from blood samples. Their expertise includes the quantification of HPV and various cancers impacted by the RAS-RAF and PI3K pathways.
Frequently Asked Questions
What is the RAS-RAF-SEQ assay?
The RAS-RAF-SEQ assay is a CLIA-validated liquid biopsy diagnostic tool that identifies significant genomic mutations associated with cancer.
What types of cancer does the RAS-RAF-SEQ target?
This assay targets mutations pertinent to colorectal, pancreatic, gallbladder, ovarian, and lung cancers.
How does the Plasma-Safe-SeqS technology work?
The Plasma-Safe-SeqS technology retains all molecules during analysis, boosting detection of low-frequency genomic mutations with high sensitivity.
Who can benefit from the RAS-RAF-SEQ assay?
Pharmaceutical developers and clinical trial researchers can utilize the assay for better insights into cancer treatment strategies.
Is Sysmex Inostics associated with any larger corporations?
Yes, Sysmex Inostics operates as a subsidiary of Sysmex Corporation, located in Japan, and specializes in innovative medical diagnostics.
